Skip to main content

Table 2 Linear regression analyses of C-reactive protein and plasma albumin levels as dependent variables and patient characteristics as explanatory variables on date of diagnosis of acute myeloid leukaemia (AML), based on 491 specimens with both CRP and PA measured

From: Longitudinal trajectory patterns of plasma albumin and C-reactive protein levels around diagnosis, relapse, bacteraemia, and death of acute myeloid leukaemia patients

Patient characteristics on date of diagnosis of AML C-reactive protein Plasma albumin
Crude analysis Adjusted analysisa Crude analysis Adjusted analysisa
Sex
 Females 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 Males 3.80 (−10.5/18.1)b 1.78 (− 12.1/15.7) −1.00 (− 2.10/0.10) − 1.01 (− 2.02/0.00)
Age group, years
 15–64 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 65–80 5.76 (−9.97/21.5) 1.29 (−14.9/17.5) −2.01 (− 3.18/−0.84)c −1.15 (− 2.32/0.02)
  + 80 −3.60 (− 24.1/16.9) − 16.5 (− 37.6/4.57) −4.46 (−5.99/− 2.94) − 2.76 (− 4.28/− 1.24)
Body mass index (kg/m^2)
  < 18.5 −15.3 (−60.4/29.9) −19.1 (−63.4/25.1) −3.32 (−6.78/0.14) − 2.54 (− 5.73/0.65)
 18.5–24.9 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 25–29.9 4.12 (− 14.0/22.2) 4.36 (−13.5/22.2) 0.31 (− 1.07/1.70) 0.08 (− 1.21/1.37)
  ≥ 30 −8.81 (−30.6/13.0) −6.27 (− 27.6/15.0) 1.33 (− 0.34/3.00) 0.74 (− 0.80/2.28)
 Unknown 30.6 (10.7/50.6) 17.3 (−2.84/37.4) − 2.20 (− 3.72/− 0.67) − 0.26 (− 1.71/1.20)
Charlson comorbidity index
 0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 1–2 5.68 (− 10.3/21.7) 5.05 (− 11.2/21.3) − 1.23 (− 2.46/0.01) − 0.33 (− 1.50/0.84)
  > 2 8.07 (− 13.5/29.6) −2.91 (− 24.7/18.9) −1.89 (− 3.54/− 0.25) 0.35 (− 1.23/1.92)
WHO performance status
 0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 1 12.4 (− 6.02/30.8) 12.3 (− 6.40/31.0) −2.38 (− 3.73/− 1.03) −2.18 (− 3.53/− 0.84)
 2 36.1 (13.6/58.6) 36.7 (13.1/60.3) −4.98 (− 6.63/− 3.34) − 4.21 (− 5.91/− 2.51)
 3/4 74.9 (51.2/98.6) 68.1 (42.2/94.0) −8.41 (− 10.1/− 6.67) − 7.54 (− 9.41/− 5.67)
Neutrophil granulocytes (10^9/L)
  < 0.5 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 0.5–0.9 10.7 (− 13.0/34.5) 5.01 (− 18.0/28.1) − 0.19 (− 2.00/1.62) 0.65 (−1.02/2.31)
 1.0–1.4 15.1 (−14.2/44.5) 1.25 (− 27.2/29.7) − 0.55(− 2.79/1.68) 0.55 (− 1.51/2.60)
  ≥ 1.5 17.9 (0.37/35.5) 10.1 (−7.22/27.3) −2.16 (− 3.50/− 0.82) −1.10 (− 2.34/0.15)
 Unknown 11.7 (− 11.8/35.2) 1.96 (− 20.9/24.9) −2.73 (− 4.52/− 0.94) −2.00 (− 3.65/− 0.34)
Blast percentage, bone marrow biopsy
 0–19 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 20–39 18.1 (− 61.1/97.2) 31.1 (− 46.3/109) 3.71 (−2.48/9.90) 2.49 (− 3.10/8.08)
 40–59 21.9 (− 57.8/102) 31.9 (− 46.0/110) 2.91 (− 3.32/9.14) 1.65 (− 3.98/7.28)
 60–79 31.0 (− 48.7/111) 40.9 (− 36.9/119) 3.73 (− 2.51/9.96) 2.18 (− 3.43/7.80)
 80–100 52.4 (− 27.5/132) 63.0 (− 15.2/141) 3.58 (− 2.66/9.83) 2.05 (− 3.60/7.69)
 Unknown 62.1 (−21.2/145) 55.6 (− 25.4/137) 2.28 (− 4.22/8.79) 2.96 (− 2.89/8.81)
  1. aAdjusted for all covariates in Table 2
  2. bCoefficient (95% confidence interval)
  3. cBold types: statistically significant (p < 0.05)